Legal & General Group
AVDL

Legal & General Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Legal & General Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-114,651
Closed -$2.47M – 3368
2025
Q4 		$2.47M Sell
114,651
-11,248
-9% -$218K ﹤0.01% 1891
2025
Q3 		$1.92M Buy
125,899
+2,361
+2% +$30.7K ﹤0.01% 1995
2025
Q2 		$1.09M Buy
123,538
+39,223
+47% +$345K ﹤0.01% 2209
2025
Q1 		$660K Sell
84,315
-424
-0.5% -$3.55K ﹤0.01% 2314
2024
Q4 		$891K Buy
84,739
+14,712
+21% +$179K ﹤0.01% 2280
2024
Q3 		$918K Buy
70,027
+58,602
+513% +$893K ﹤0.01% 2263
2024
Q2 		$161K Buy
+11,425
New +$186K ﹤0.01% 2693

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Legal & General Group's AVDL Position: Q1 2026 in Review

Legal & General Group sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 114,651 shares — an estimated $2.47M sold.

Legal & General Group first reported a position in AVDL in Q2 2024 and held it in 7 quarters. The position peaked at $2.47M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Legal & General Group reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Legal & General Group sold 114,651 Avadel Pharmaceuticals shares in Q1 2026, an estimated $2.47M.
  • Legal & General Group first reported a position in Avadel Pharmaceuticals in Q2 2024 and held it in 7 quarters.
  • Legal & General Group's Avadel Pharmaceuticals position peaked at $2.47M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.